Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Influenza Virus Vaccines and Vaccination
share announcement

Influenza Virus Vaccines and Vaccination

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Influenza Virus Vaccines".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 2958

Special Issue Editor

Prof. Dr. Shigui Yang

E-Mail Website
Guest Editor
School of Public Health, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Interests: epidemiology and prevention of infectious diseases (with a focus on influenza, H7N9/H5N1 avian influenza, and COVID-19, as well as viral hepatitis); big data mining in infectious disease research; research in public health models

Special Issue Information

Dear Colleagues, 

We are pleased to announce a Special Issue dedicated to the theme "Influenza Virus Vaccines and Vaccination”. We invite researchers and experts from diverse backgrounds to submit high-quality research papers and reviews that explore the immunopathogenic mechanisms and strategies for controlling influenza viruses. We encourage scientists to share their experimental findings and theoretical insights in the form of open-access publications. To ensure the reproducibility of research, we request contributors to provide comprehensive details of their experiments. Additionally, authors are encouraged to include computational data or supplementary materials in their submissions, along with providing complete procedural information.

Through promoting interdisciplinary collaboration and facilitating the dissemination of detailed research outcomes, the primary objective of this Special Issue is to enhance our comprehension of the intricate immunopathogenic mechanisms associated with influenza viruses, while also fostering the development of innovative approaches for the effective management of influenza virus infections.

We look forward to receiving your valuable contributions to this timely and significant Special Issue.

Best regards,

Prof. Dr. Shigui Yang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • influenza virus
  • immunopathogenic mechanisms
  • prevention and control
  • epidemiologic feature
  • immune responses to influenza virus
  • influenza vaccine development and efficacy evaluation
  • influenza vaccine technology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 240 KiB  
Article
Hospital-Based Influenza and Pneumococcal Vaccination for Cancer Patients on Active Treatment and Their Family Members during the COVID-19 Pandemic in Italy: A Single-Center Experience
by Davide Dalu, Anna Lisa Ridolfo, Lorenzo Ruggieri, Maria Silvia Cona, Agostino Riva, Davide De Francesco, Chiara Tricella, Cinzia Fasola, Sabrina Ferrario, Anna Gambaro, Benedetta Lombardi Stocchetti, Valeria Smiroldo, Gaia Rebecchi, Sheila Piva, Giorgia Carrozzo, Spinello Antinori and Nicla La Verde
Vaccines 2024, 12(6), 642; https://doi.org/10.3390/vaccines12060642 - 8 Jun 2024
Cited by 1 | Viewed by 1097
Abstract
In patients with cancer, tumor- and treatment-induced immunosuppression are responsible for a four-fold increase in morbidity and mortality caused by influenza and invasive Streptococcus pneumoniae infections compared to the general population. The main oncology societies strongly recommend vaccination in patients with cancer to [...] Read more.
In patients with cancer, tumor- and treatment-induced immunosuppression are responsible for a four-fold increase in morbidity and mortality caused by influenza and invasive Streptococcus pneumoniae infections compared to the general population. The main oncology societies strongly recommend vaccination in patients with cancer to prevent these infections. However, vaccine hesitancy is a main concern in this population. The aim of this study was to assess the feasibility of in-hospital vaccination for patients under anticancer treatment and their family members (FMs) against influenza and pneumococcal infections during the COVID-19 pandemic in order to increase vaccine coverage. This was a single-center, prospective, observational study conducted at the Department of Oncology of Luigi Sacco University Hospital (Milan, Italy) between October 2020 and April 2021. The main primary outcome was the incidence of influenza-like illness (ILI) and pneumococcal infections. The main secondary outcome was safety. A total of 341 subjects were enrolled, including 194 patients with cancer and 147 FMs. The incidence of ILI was higher among patients than among FMs (9% vs. 2.7%, OR 3.92, p = 0.02). Moreover, two subjects were diagnosed with pneumococcal pneumonia. The most frequent vaccine-related AEs were pain in the injection site (31%) and fatigue (8.7%). In conclusion, this hospital-based vaccination strategy was feasible during the COVID-19 pandemic, representing a potential model to maximize vaccine coverage during a public health emergency. Full article
(This article belongs to the Special Issue Influenza Virus Vaccines and Vaccination)
13 pages, 1023 KiB  
Article
Cost-Effectiveness of Adjuvanted Quadrivalent Influenza Vaccine for Adults over 65 in France
by Marc Paccalin, Gaëtan Gavazzi, Quentin Berkovitch, Henri Leleu, Romain Moreau, Emanuele Ciglia, Nansa Burlet and Joaquin F. Mould-Quevedo
Vaccines 2024, 12(6), 574; https://doi.org/10.3390/vaccines12060574 - 24 May 2024
Viewed by 1411
Abstract
Background: In France, influenza accounts for an average of over one million consultations with GPs, 20,000 hospitalizations, and 9000 deaths per year, particularly among the over-65s. This study evaluates the cost-effectiveness of the adjuvanted quadrivalent influenza vaccine (aQIV) compared to standard (SD-QIV) and [...] Read more.
Background: In France, influenza accounts for an average of over one million consultations with GPs, 20,000 hospitalizations, and 9000 deaths per year, particularly among the over-65s. This study evaluates the cost-effectiveness of the adjuvanted quadrivalent influenza vaccine (aQIV) compared to standard (SD-QIV) and high-dose (HD-QIV) quadrivalent influenza vaccines for individuals aged 65 and older in France. Methods: The age-structured SEIR transmission model, calibrated to simulate a mean influenza season, incorporates a contact matrix to estimate intergroup contact rates. Epidemiological, economic, and utility outcomes are evaluated. Vaccine effectiveness and costs are derived from literature and national insurance data. Quality of life adjustments for influenza attack rates and hospitalizations are applied. Deterministic and probabilistic analyses are also conducted. Results: Compared to SD-QIV, aQIV demonstrates substantial reductions in healthcare utilization and mortality, avoiding 89,485 GP consultations, 2144 hospitalizations, and preventing 1611 deaths. Despite an investment of EUR 110 million, aQIV yields a net saving of EUR 14 million in healthcare spending. Compared to HD-QIV, aQIV saves 62 million euros on vaccination costs. Cost-effectiveness analysis reveals an incremental cost-effectiveness ratio of EUR 7062 per QALY. Conclusions: This study highlights the cost-effectiveness of aQIV versus SD-QIV and HD-QIV, preventing influenza cases, hospitalizations, and deaths. Full article
(This article belongs to the Special Issue Influenza Virus Vaccines and Vaccination)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop